Insider buying last 90 days
No open-market insider purchases were filed for TDOC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TDOC insider filing, plotted on the chart in Gekko.Open TDOC in Gekko
NYSE: TDOC
Teladoc Health (TDOC) Stock Analysis & Forecast
Oct 12 close
$5.92+0.15 (+2.6%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on Teladoc's expansion of its Solo connected care platform, with two new AI-powered tools, SoloVitals and SoloScribe, introduced to help hospitals with contactless vital sign capture and automated clinical documentation. Coverage of the launch was largely positive, with one piece noting the stock as potentially undervalued against an outside fair value estimate of $15.00, while another pointed to a recent 4% decline in Q2 revenue alongside the product news. A separate comparison piece weighed Teladoc against peer Schrodinger on business fundamentals.
Shares closed at $5.92, up 2.6% on the day, but remain below both the 50-day average of $6.30 and the 200-day average of $6.52, with the shorter average also below the longer one. The GekkoIndex reads 62.2, placing the stock in the Accumulation zone, down 6.2 points over the past five sessions. Price sits 42.6% below Gekko Fair Value of $10.31.
Teladoc reports earnings on 28 October, 15 days out and within a typical 20-trading-day holding window; the prior print saw a -29.7% reaction despite a smaller-than-expected loss. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over the next 20 trading days has averaged +1.1% across 5 years, positive in 3 of them. Analyst consensus among 16 firms carries a $7.59 target.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Teladoc Health price vs fair value
Close $5.92200-day averageGekko Fair Value $10.31
Teladoc Health quick facts
- Market cap
- $1.08B
- P/E ratio
- —
- Forward P/E
- 303
- EPS, TTM
- −$0.99
- Revenue, TTM
- $2.49B
- Profit margin
- -7.1%
- Dividend yield
- —
- Beta
- 2.14
- Volume
- 3.25M avg 3.63M
- 1-year return
- −33.1%
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±11.8%
- 50-day average
- $6.30
- 200-day average
- $6.52
- Next earnings
- Oct 28 after close
- Shares outstanding
- 181.7M
Teladoc Health swing-trade checklist
Teladoc Health scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $5.92 is below the 50-day ($6.30) and 200-day ($6.52) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
62.2, Accumulation
Reading 62.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
42.6% below
Price is 42.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 16 days
Reports on Oct 28, 2026, 16 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.1% on average
From this point in the calendar, the next 20 trading days averaged +1.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Teladoc Health stock chart and price history
Teladoc Health closed at $5.92 on Oct 12, 2026, −33.1% over the past year, inside a 52-week range of $4.40 to $9.89.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −3.9%
- 3 months
- −36.1%
- 6 months
- +13.4%
- 1 year
- −33.1%
The full TDOC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TDOC in Gekko
Follow Teladoc Health through every session
Put TDOC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TDOC in GekkoFree for 7 days. No credit card required.
About Teladoc Health
Teladoc Health provides virtual healthcare services to patients in the United States and abroad, addressing everything from everyday medical concerns to ongoing conditions such as diabetes, high blood pressure, kidney disease, cancer, heart failure, and mental health challenges. Its offerings include general and specialist virtual visits, chronic condition management, second opinion consultations, and emotional wellbeing support, built around a shared technology platform. The company is recognized for operating under several brand names, including Teladoc, Livongo, and BetterHelp.
Its customers span a broad mix of organizations and individuals, among them employers, health insurers, hospitals and health systems, and financial services firms, alongside people seeking care directly. This spread of clients reflects a business built around delivering remote health services through multiple channels rather than a single point of sale.
Teladoc Health traces its origins to 2002 and was previously known as Teladoc, Inc. before adopting its current name in 2018. The company is headquartered in Purchase, New York, and its shares trade on the NYSE under the ticker TDOC.
- Listed
- NYSE
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- teladochealth.com
Teladoc Health GekkoIndex: the smart money zone
Teladoc Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.2, in the Accumulation zone, down 6.2 points over five sessions.
62.2Accumulation
Down 6.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 87 | −1.9% | −5.3% | ||
| Accumulation (current zone) | 266 | −0.2% | −2.4% | ||
| Neutral | 295 | −0.4% | −0.3% | ||
| Distribution | 32 | −1.6% | −7.8% | ||
| Selling | 2 | Too few readings yet | |||
Average TDOC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the TDOC price, zone by zone.Track TDOC in Gekko
Is Teladoc Health stock overvalued? Gekko Fair Value
Teladoc Health trades 42.6% below Gekko Fair Value of $10.31, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Teladoc Health shares are worth, recalculated every trading day.
$10.31
Gekko Fair Value, Oct 10, 2026
42.6% Undervalued
At the end of Aug 2026 the price was 46.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open TDOC in Gekko
Teladoc Health insider and Congress trading
No open-market insider purchases were filed for Teladoc Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TDOC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TDOC, plotted on the chart in Gekko.Open TDOC in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds TDOC.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Teladoc Health earnings: next date and track record
Teladoc Health reports on Oct 28, 2026, after the close (16 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 28, 2026
Expected after the close, 16 days away
- EPS estimate
- −$0.22
- Revenue estimate
- $588.5M
7 of 8reports beat the EPS estimate
±10.4%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 29, 2026 AI summary
- What they said
- Teladoc's Q2 2026 earnings call emphasized that consolidated results were within guidance, with Integrated Care performing above midpoint on revenue and adjusted EBITDA, and BetterHelp showing mixed results: insurance-related revenue near the high end of expectations but overall segment revenue pressured by lower cash-pay revenue. Management highlighted the national rollout of BetterHelp insurance, the launch of Teladoc 1 (a connected care model), and multiple initiatives to scale insurance capacity (provider recruitment, delegated credentialing, onboarding improvements, platform and scheduling efficiencies and AI tools). They reiterated their focus on shifting marketing/ad spend to align with insurance capacity and said insurance will likely have lower gross margins than cash pay but more durable lifetime value. Integrated Care saw solid selling-season trends, bundle adoption (notably weight/obesity), and positive early traction for Teladoc 1. Management acknowledged demand outpacing therapist supply for BetterHelp insurance, causing temporary capacity constraints and prompting reprioritization of resources (including near-term deprioritization of international BetterHelp investment). Overall tone was cautious but constructive—management reaffirmed guidance and described specific remediation steps while acknowledging headwinds in cash-pay behavior and capacity constraints.
- Guidance
- Reinstated BetterHelp insurance revenue range of $90 million to $105 million (presumably for 2026 period referenced); consolidated results were within previously provided guidance ranges; management maintained adjusted EBITDA expectations (no specific numeric EBITDA guidance provided on the call beyond reference to prior guidance ranges).
- Risks flagged
- Capacity constraints in BetterHelp (demand outpacing available therapists), lower gross margin percentage expected as insurance scales vs. cash-pay, potential continued declines in U.S. cash-pay demand, competitive pressures across virtual and chronic care markets, recruitment/onboarding challenges for therapists, variability by market/payer, and macro/regulatory pressures affecting selling season for Integrated Care.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 29, 2026 | −$0.21 est −$0.24 | $606.9M est $615.4M | −29.7% |
| Apr 29, 2026 | −$0.28 est −$0.39 | $613.8M est $610.9M | +1.0% |
| Feb 25, 2026 | −$0.10 est −$0.18 | $642.3M est $635.3M | +17.8% |
| Oct 29, 2025 | −$0.21 est −$0.26 | $626.4M est $635.3M | +4.5% |
| Jul 29, 2025 | −$0.19 est −$0.27 | $631.9M est $627.7M | −9.8% |
| Apr 30, 2025 | −$0.53 est −$0.34 | $629.4M est $619.2M | −4.6% |
| Feb 26, 2025 | −$0.25 est −$0.29 | $640.5M est $639.4M | −15.0% |
| Oct 30, 2024 | −$0.19 est −$0.28 | $640.5M est $640.4M | +0.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Teladoc Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Teladoc Health is $7.59, +28.2% from the last close, from 16 firms rating the stock in the last 90 days.
$7.59consensus 12-month target, +28.2% from the last close
Now $5.92Avg $7.59
Low $5.50High $10.50
Each firm’s latest rating in the last 90 days: 16 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Bank of America Securities | $10.50 | +77.4% |
| Sep 15 | Bank of America Securities | $10.50 | +77.4% |
| Sep 1 | Truist Financial | — | — |
| Aug 31 | Canaccord Genuity | $10 | +68.9% |
| Aug 31 | Bank of America Securities | $10.50 | +77.4% |
−2.4%average 20-day move after past Accumulation readings
+1.1%average move over the next 20 trading days in the last 5 years
±3.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Teladoc Health seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Teladoc Health averaged +1.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.0% | 3 of 5 |
| Next 10 trading days | +2.8% | 2 of 5 |
| Next 15 trading days | +5.0% | 3 of 5 |
| Next 20 trading days | +1.1% | 3 of 5 |
| Next 30 trading days | −6.5% | 1 of 5 |
For scale, TDOC’s typical 20-trading-day move in either direction is about 11.8%.
Teladoc Health market cap and key statistics
Teladoc Health’s market cap is $1.08B and revenue of $2.49B over the last twelve months.
Valuation
- Market cap
- $1.08B
- Forward P/E
- 303
- EPS, TTM
- −$0.99
- Gekko Fair Value
- $10.31
Trading
- Volume
- 3.25M
- Avg volume, 20 days
- 3.63M
- 52-week high
- $9.89
- 52-week low
- $4.40
- Shares outstanding
- 181.7M
Financials
- Revenue, TTM
- $2.49B
- Profit margin
- -7.1%
- Return on equity
- -13%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.14
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±11.8%
Teladoc Health stock news this week
Coverage of Teladoc Health this week reads positive: 9 positive, 4 neutral and 0 negative headlines.
- Analyzing Teladoc Health (NYSE:TDOC) & Schrodinger (NASDAQ:SDGR)Defense World, Oct 12
- Teladoc Strengthens Solo Platform With New AI-Powered Care ToolsTradingView, Oct 8
- A fund adviser reports 9.1 million Teladoc Health (TDOC) shares held by its funds.Stock Titan, Oct 8
- Teladoc Health Expands Solo Connected Care Platform withGlobeNewswire, Oct 8
- Teladoc Health stock launches new AI tools for hospitalsAD HOC NEWS, Oct 8
- Teladoc Health (TDOC) Could Be 63% Undervalued Following Its New AI ToolsYahoo Finance, Oct 8
Teladoc Health peers
Teladoc Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
Teladoc Health stock FAQ
What is Teladoc Health’s market cap?
Teladoc Health’s market cap is $1.08B at the Oct 12, 2026 close of $5.92, with 181.7M shares outstanding.
What is the Teladoc Health stock forecast?
The consensus analyst 12-month price target for Teladoc Health is $7.59, +28.2% from the last close. Of the 16 firms that rated the stock in the last 90 days, 4 rate it a buy, 12 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Teladoc Health stock overvalued or undervalued?
On Gekko’s estimate Teladoc Health is undervalued: the Oct 12, 2026 close of $5.92 is 42.6% below Gekko Fair Value of $10.31. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Teladoc Health report earnings next?
Teladoc Health is expected to report on Oct 28, 2026, after the market closes (16 days away). Analysts expect earnings of −$0.22 per share on revenue of $588.5M. Teladoc Health beat the earnings estimate in 7 of its last 8 reports, moving 10.4% on average across the report.
What is Teladoc Health’s 52-week high and low?
Teladoc Health’s 52-week high is $9.89 and its 52-week low is $4.40; it closed at $5.92 on Oct 12, 2026, −33.1% over the past year. Over the last five years the shares peaked at $156.82 on Nov 4, 2021.
Is Teladoc Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Teladoc Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.